Toxicokinetics Laboratory & Regulatory Toxicology Group, CSIR-Indian Institute of Toxicology Research (CSIR-IITR), Lucknow, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India; Analytical Chemistry Laboratory & Regulatory Toxicology Group, CSIR-Indian Institute of Toxicology Research (CSIR-IITR), Lucknow, India.
Toxicokinetics Laboratory & Regulatory Toxicology Group, CSIR-Indian Institute of Toxicology Research (CSIR-IITR), Lucknow, India; Analytical Chemistry Laboratory & Regulatory Toxicology Group, CSIR-Indian Institute of Toxicology Research (CSIR-IITR), Lucknow, India.
Chemosphere. 2021 Jun;273:129624. doi: 10.1016/j.chemosphere.2021.129624. Epub 2021 Jan 18.
Despite showing serious health consequences and widespread exposure, the toxicokinetic information required to evaluate the health risks of BPS is insufficient. Thus, we aim to describe the comprehensive toxicokinetics of BPS and its glucuronide (BPS-G) and sulfate (BPS-S) metabolites in rats. Simultaneous quantification of BPS and its metabolites (authentic standards) was accomplished using UPLC-MS/MS method. BPS displayed rapid absorption, extensive metabolism and fast elimination after oral administration. Following intravenous administration, BPS exhibited CL (8.8 L/h/kg) higher than the rat hepatic blood flow rate suggesting the likelihood of extrahepatic clearance. The CL value differed from those reported previously (sheep and piglets) and the probable reason could be attributed to dose- and/or interspecies differences. BPS was extensively metabolized and excreted primarily through urine as BPS-G (∼56%). BPS and BPS-S exhibited a high protein binding capacity in comparison to BPS-G. In in vitro metabolic stability study, BPS was predominantly metabolized through glucuronidation. The predicted in vivo hepatic clearance of BPS suggested it to be a high and intermediate clearance chemical in rats and humans, respectively. The significant interspecies difference observed in the clearance of BPS between rats and humans indicated that toxicokinetics of BPS should be considered for health risk assessment in humans.
尽管 BPS 已经显示出严重的健康后果和广泛的暴露,但评估其健康风险所需的毒代动力学信息仍然不足。因此,我们旨在描述 BPS 及其葡萄糖醛酸(BPS-G)和硫酸盐(BPS-S)代谢物在大鼠体内的综合毒代动力学。采用 UPLC-MS/MS 方法同时定量测定 BPS 及其代谢物(标准品)。BPS 经口服给药后,吸收迅速,代谢广泛,消除迅速。静脉注射后,BPS 的 CL(8.8 L/h/kg)高于大鼠肝血流量,提示可能存在肝外清除。CL 值与之前报道的(绵羊和仔猪)不同,可能的原因是剂量和/或种属差异。BPS 被广泛代谢,主要通过尿液以 BPS-G(约 56%)形式排泄。与 BPS-G 相比,BPS 和 BPS-S 具有较高的蛋白结合能力。在体外代谢稳定性研究中,BPS 主要通过葡萄糖醛酸化代谢。BPS 的预测体内肝清除率表明,它在大鼠和人类中分别为高清除率和中清除率化学物质。大鼠和人类之间 BPS 清除率的显著种间差异表明,在进行人类健康风险评估时,应考虑 BPS 的毒代动力学。